About Cortalix
Cortalix is a company based in Groningen (Netherlands) founded in 2007 by Herman Steen. Cortalix has raised $1.08 million across 1 funding round from investors including Rabobank and Future Tech Ventures. Cortalix offers products and services including Synthetic sdAb Platform, ImmunoPET Services, and CAR-T Immunotherapeutics. Cortalix operates in a competitive market with competitors including Roquette, DENAVA, MVMD, Winclove and Emergent Health Corp, among others.
- Headquarter Groningen, Netherlands
- Founders Herman Steen
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cortalix Bv
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.08 M (USD)
in 1 rounds
-
Latest Funding Round
$1.08 M (USD), Seed
Mar 11, 2025
-
Investors
Rabobank
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cortalix
Cortalix offers a comprehensive portfolio of products and services, including Synthetic sdAb Platform, ImmunoPET Services, and CAR-T Immunotherapeutics.
Platform for discovering synthetic single domain antibodies.
Services for antibody-based molecular imaging applications.
Development of antibodies for cancer immunotherapy treatments.
Funding Insights of Cortalix
Cortalix has successfully raised a total of $1.08M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.08 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cortalix
Cortalix has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Rabobank and Future Tech Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in technology and impact startups.
|
Locked | Locked | Locked | |
|
Commercial banking services are provided by Rabobank from Utrecht, Netherlands.
|
Locked | Locked | Locked |
Investor details for Cortalix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cortalix
Investment portfolio details for Cortalix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cortalix
Detailed financials for Cortalix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cortalix Comparisons
Peer comparison for Cortalix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cortalix
Cortalix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Roquette, DENAVA, MVMD, Winclove and Emergent Health Corp, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Plant-based pharma, nutraceuticals, and cosmetics are manufactured as a CDMO.
|
|
| Locked | Locked | Locked |
Investments are managed in health and digital sectors.
|
|
| Locked | Locked | Locked |
Biotech company focused on manufacturing neutraceuticals
|
|
| Locked | Locked | Locked |
Probiotic food supplements are developed and produced by Winclove.
|
|
| Locked | Locked | Locked |
Manufacturer of weight loss and energy supplements
|
|
| Locked | Locked | Locked |
Custom contract manufacturer of quality dietary supplements and homeopathic products.
|
Detailed competitors of Cortalix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cortalix
Complete news archive for Cortalix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cortalix
Cortalix was founded in 2007 and raised its 1st funding round 18 years after it was founded.
Cortalix is headquartered in Groningen, Netherlands. It is registered at Groningen, Groningen, Netherlands.
Herman Steen is the current CEO of Cortalix. They have also founded this company.
Cortalix is a funded company, having raised a total of $1.08M across 1 funding round to date.
Cortalix was founded in 2007 in Groningen, Netherlands, as a biotechnology firm focused on radiopharmaceuticals. Synthetic nanobody libraries are utilized to identify candidates for molecular imaging diagnostics and targeted radiotherapeutics, particularly for fibrogenesis-related membrane receptors and proteins. Operations include pipeline development in immunoPET and immunoRT applications. Collaborations with other organizations are maintained, and research grants have been secured to support technology advancement.
Cortalix offers Synthetic sdAb Platform, ImmunoPET Services, and CAR-T Immunotherapeutics.
Cortalix has 2 investors. Key investors include Rabobank, and Future Tech Ventures.